We Think Shareholders Will Probably Be Generous With Vistin Pharma ASA's (OB:VISTN) CEO Compensation

Key Insights

• Vistin Pharma's Annual General Meeting to take place on 22nd of May
• Total pay for CEO Magnus Tolleshaug includes kr2.59m salary
• Total compensation is similar to the industry average
• Vistin Pharma's EPS grew by 336% over the past three years while total shareholder return over the past three years was 49%

Our free stock report includes 1 warning sign investors should be aware of before investing in Vistin Pharma. Read for free now.

We have been pretty impressed with the performance at Vistin Pharma ASA (OB:VISTN) recently and CEO Magnus Tolleshaug deserves a mention for their role in it. Coming up to the next AGM on 22nd of May, shareholders would be keeping this in mind. This would also be a chance for them to hear the board review the financial results, discuss future company strategy and vote on any resolutions such as executive remuneration. Here is our take on why we think CEO compensation is not extravagant.

Check out our latest analysis for Vistin Pharma

How Does Total Compensation For Magnus Tolleshaug Compare With Other Companies In The Industry?

Our data indicates that Vistin Pharma ASA has a market capitalization of kr1.1b, and total annual CEO compensation was reported as kr3.6m for the year to December 2024. That's a notable increase of 59% on last year. In particular, the salary of kr2.59m, makes up a huge portion of the total compensation being paid to the CEO.

In comparison with other companies in the Norway Pharmaceuticals industry with market capitalizations under kr2.1b, the reported median total CEO compensation was kr3.6m. So it looks like Vistin Pharma compensates Magnus Tolleshaug in line with the median for the industry.

Component	2024	2023	Proportion (2024)
Salary	kr2.6m	kr1.8m	73%
Other	kr973k	kr426k	27%
Total Compensation	kr3.6m	kr2.2m	100%

Speaking on an industry level, nearly 51% of total compensation represents salary, while the remainder of 49% is other remuneration. It's interesting to note that Vistin Pharma pays out a greater portion of remuneration through salary, compared to the industry. If total compensation veers towards salary, it suggests that the variable portion - which is generally tied to performance, is lower.

A Look at Vistin Pharma ASA's Growth Numbers

Vistin Pharma ASA has seen its earnings per share (EPS) increase by 336% a year over the past three years. The trailing twelve months of revenue was pretty much the same as the prior period.

Overall this is a positive result for shareholders, showing that the company has improved in recent years. It's always a tough situation when revenues are not growing, but ultimately profits are more important. While we don't have analyst forecasts for the company, shareholders might want to examine this detailed historical graph of earnings, revenue and cash flow.

Has Vistin Pharma ASA Been A Good Investment?

We think that the total shareholder return of 49%, over three years, would leave most Vistin Pharma ASA shareholders smiling. This strong performance might mean some shareholders don't mind if the CEO were to be paid more than is normal for a company of its size.

To Conclude...

Given the company's decent performance, the CEO remuneration policy might not be shareholders' central point of focus in the AGM. However, investors will get the chance to engage on key strategic initiatives and future growth opportunities for the company and set their longer-term expectations.

CEO compensation is a crucial aspect to keep your eyes on but investors also need to keep their eyes open for other issues related to business performance. We did our research and spotted 1 warning sign for Vistin Pharma that investors should look into moving forward.

Arguably, business quality is much more important than CEO compensation levels. So check out this free list of interesting companies that have HIGH return on equity and low debt.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.